🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jamunarani Veeraraghavan

Baylor College of Medicine

ORCID: 0000-0002-9524-9487
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4 , Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers”.

A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4 , Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2769
N/A
0DataRank · unranked
17 citations

Jamunarani Veeraraghavan, Ying Tan, Jinah Kim, Xian Wang, Suet Kee Loo +4 more

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

Breast Cancer Research(2020)10.1186/s13058-020-01325-3
N/A
0DataRank · unranked
35 citations

Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee +4 more

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.26.149948
N/A
0DataRank · unranked
3 citations

Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee +4 more

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-19-4191
N/A
0DataRank · unranked
94 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2961
N/A
0DataRank · unranked
12 citations

Jamunarani Veeraraghavan, Chia-Chia Liu, Xixi Cao, Lanfang Qin, Jin-Ah Kim +13 more

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

npj Breast Cancer(2021)10.1038/s41523-021-00274-0
N/A
0DataRank · unranked
11 citations

Carolina Gutiérrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea +16 more

Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.522
N/A
0DataRank · unranked
0 citations

Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Lieveke Ameye, Marianne Paesmans, Sarra El-Abed +13 more

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Cell Reports(2023)10.1016/j.celrep.2023.112821
N/A
0DataRank · unranked
22 citations

Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J. Shea, Sarmistha Nanda +17 more

Data from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer

(2023)10.1158/1078-0432.c.6531045
N/A
0DataRank · unranked
0 citations

Jamunarani Veeraraghavan, Chia-Chia Liu, Xixi Cao, Lanfang Qin, Jinah Kim +13 more

Data from A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers

(2023)10.1158/1078-0432.c.6530286
N/A
0DataRank · unranked
0 citations

Jamunarani Veeraraghavan, Ying Tan, Jinah Kim, Xian Wang, Suet Kee Loo +4 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603
N/A
0DataRank · unranked
0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603.v1
N/A
0DataRank · unranked
0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2‐positive breast cancer

British Journal of Pharmacology(2025)10.1111/bph.17463
N/A
0DataRank · unranked
6 citations

Raksha R. Bhat, Micah Castillo, Sung Yun Jung, Suhas Vasaikar, Sarmistha Nanda +12 more